futibatinib
otsuka pharmaceuticals
[' futi']
hcq does not prevent ra in ccp+ pts w/out clinical arthritis! stop ra: rct hcq vs. pbo in pts at-risk interim analysis 140+ pts
ra development hcq 34% vs. pbo 36% trial interrupted as met futility criteria. abs#1604 #acr22 #acrbest 
MD, PhD Institute of Infection and Immunity @UofGlasgow UK. Past Co-chair of @EULAR Synovitis Study Group. CrossFit athlete and Mountains lover. Views my own.